Aduro BioTech

LEAD THERAPEUTIC CRS-207

CRS-207 is a Listeria strain engineered to express Mesothelin, an antigen commonly over-expressed in a range of solid tumors. The CRS-207 Phase 1 safety trial examined 17 patients with advanced, treatment-refractory, mesothelin-expressing tumors: 7 pancreatic, 5 mesothelioma, 3 non-small-cell lung and 2 ovarian. Analysis after the completion of the trial revealed that, despite an expected survival of 3-5 months for all subjects, 6 out of 17 subjects lived 15 months or longer. For more information, please see Clinical Trials.

Learn More About Us

NEWS

November 10, 2011
Aduro BioTech patent upheld by USPTO. Read it here.

October 11, 2011
Aduro BioTech announces first patient treated in Phase 2 pancreatic cancer trial. Read it here.

September 22, 2011
Aduro BioTech, Inc. appoints Thomas Dubensky, Jr. as Chief Scientific Officer. Read it here.

See More News